Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Great Bay Bio's 3D Advisory Board Science Committee Welcomes Another New Arrival
BiotechnologyCompany Update

Great Bay Bio's 3D Advisory Board Science Committee Welcomes Another New Arrival

August 26, 2019 10:05 PM

HONG KONG, CHINA / ACCESSWIRE / August 26, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce that following the successful establishment of the 3D Advisory Board in the middle of this month, the Science Sub-Committee welcomes another new key member, Dr. Mark McHale, to the team. Dr. Mark McHale received...

Read more
ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress
BiotechnologyConferences

ReShape Lifesciences(TM) to Highlight Products at IFSO 24th World Congress

August 22, 2019 8:30 AM

SAN CLEMENTE, CA / ACCESSWIRE / August 22, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company will be attending the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress, taking place at Ifema Palacio Municipal in Madrid, Spain, from September 3-7, 2019. ReShape Lifesciences™...

Read more
American CryoStem Engages IRB for IND Filling with the FDA
BiotechnologyCompany Update

American CryoStem Engages IRB for IND Filling with the FDA

August 22, 2019 7:00 AM

EATONTOWN, NJ / ACCESSWIRE / August 22, 2019 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has engaged The Institute of Regenerative Cellular Medicine (IRCM) www.ircm.org to perform the Institutional Review Board (IRB) requirement...

Read more
Dyadic to Present at Four Upcoming Investor Conferences in September
BiotechnologyConferences

Dyadic to Present at Four Upcoming Investor Conferences in September

August 21, 2019 4:00 PM

JUPITER, FL / ACCESSWIRE / August 21, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive...

Read more
Hancock Jaffe Successfully Completes Two Additional VenoValve Implantations for First-in-Man Study
BiotechnologyCompany Update

Hancock Jaffe Successfully Completes Two Additional VenoValve Implantations for First-in-Man Study

August 20, 2019 8:31 AM

Eight Patients Now Part of First-in-Man Bogota Study IRVINE, CA / ACCESSWIRE / August 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in two additional patients, as part of HJLI’s first-in-man Bogota study. Eight patients have now received VenoValves as part of the initial phase of the first-in-man study. The...

Read more
HemaGenetics Announces Results of Annual General & Special Meeting of Shareholders
BiotechnologyCompany UpdateShareholder Meeting

HemaGenetics Announces Results of Annual General & Special Meeting of Shareholders

August 16, 2019 10:44 AM

VANCOUVER, BC / ACCESSWIRE / August 16, 2019 / HemaGenetics Technologies Corp. (the “Company”) is pleased to announce the results of its annual general & special meeting of its shareholders held on August 9, 2019 at 10 a.m. at Suite 300 - 1055 W. Hastings St., Vancouver, BC, Canada, V6E 2E9 (the “Meeting”). Shareholders of record as of July 12, 2019 voted at the Meeting. The purpose of the Meeting was for shareholders to attend to and vote on...

Read more
Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
BiotechnologyConference CallEarnings

Pressure BioSciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update

August 15, 2019 9:29 AM

Record Consumables Sales, Strong Growth in BaroFold & UST Services, and Launch of Revolutionary CBD Processing System Highlight the 2019 Second Quarter; Company Believes Total Revenue Will More than Double in 2020 Investor Conference Call Scheduled for Thursday, August 15, 2019 at 4:30 PM EDT SOUTH EASTON, MA / ACCESSWIRE / August 15, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale...

Read more
Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
BiotechnologyEarnings

Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update

August 15, 2019 7:35 AM

- Building momentum with recent acquisition of innovative XCART platform technology and closing of $15 million underwritten public offering - Corporate strategy shift with entry into the CAR T space positions Company to drive significant value for shareholders - Company executes on initial step in XCART development through recent signing of a research agreement enabling advancement towards its stated goal of establishing an academic...

Read more
Edesa Biotech Reports Quarterly Financial Results
BiotechnologyEarnings

Edesa Biotech Reports Quarterly Financial Results

August 14, 2019 4:05 PM

TORONTO, ON / ACCESSWIRE / August 14, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended June 30, 2019 and provided an update on its business. During the quarter, Edesa completed its reverse acquisition and Nasdaq listing, and announced plans to proceed with its clinical investigation of EB01, a novel sPLA2 inhibitor, which the company is...

Read more
Hancock Jaffe Reports Positive 90 Day Results for CoreoGraft Animal Feasibility Study
Biotechnology

Hancock Jaffe Reports Positive 90 Day Results for CoreoGraft Animal Feasibility Study

August 14, 2019 11:00 AM

Grafts Open and Fully Functional at 90 Days IRVINE, CA / ACCESSWIRE / August 14, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. For the three (3) test subjects that were evaluated via angiogram ninety (90) days post CoreoGraft bypass surgery, the CoreoGrafts are functioning...

Read more
Dyadic Reports Second Quarter 2019 Results and Recent Developments
BiotechnologyEarnings

Dyadic Reports Second Quarter 2019 Results and Recent Developments

August 13, 2019 4:00 PM

New Fully Funded Research Collaboration With a Top Tier Pharmaceutical Company Expanded Technology Platform Through Multiple Collaborations and Sublicensing Agreements Robust Scientific Data Reported Up listed to the Nasdaq Capital Market and Joined Russell Microcap® Index JUPITER, FL / ACCESSWIRE / August 13, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its...

Read more
Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update
BiotechnologyConference CallEarnings

Pressure BioSciences, Inc. to Discuss Second Quarter 2019 Financial Results and Provide Business Update

August 13, 2019 2:35 PM

Conference Call Scheduled for Thursday, August 15th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / August 13, 2019 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Second Quarter 2019 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a...

Read more
Great Bay Bio Adds Two Industry Leaders to Advisory Board
BiotechnologyMiscellaneous

Great Bay Bio Adds Two Industry Leaders to Advisory Board

August 12, 2019 12:50 AM

Great Bay Bio Adds Two Industry Leaders to Advisory Board HONG KONG, CHINA / ACCESSWIRE / August 12, 2019 / Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) development of innovative biologics, is pleased to announce the establishment of its 3D Advisory Board. The board of directors eagerly welcome two top industry elites, Dr. Katie Su and Mr. Aaron Wang, to the company....

Read more
CBDual Biotechnology Corp (subsidiary of OTC: CBDG) to Offer ORALDNA(R) Testing to Improve Oral and Systemic Health
BiotechnologyInvestor Relations

CBDual Biotechnology Corp (subsidiary of OTC: CBDG) to Offer ORALDNA(R) Testing to Improve Oral and Systemic Health

August 9, 2019 11:05 AM

THOUSAND OAKS, CA / ACCESSWIRE / August 9, 2019 / CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK:CBDG) developer of CBD based oral health products, today announced - that the Company is now offering a powerful new tool to help with gum disease diagnosis and treatment. A simple rinse test from OralDNA® Labs identifies individual genetic susceptibility to periodontal disease. With this information, clinicians are...

Read more
Molecular Partners Announces Appointment of Nicolas Leupin, M.D., MBA, as Chief Medical Officer
BiotechnologyInvestor Relations

Molecular Partners Announces Appointment of Nicolas Leupin, M.D., MBA, as Chief Medical Officer

August 8, 2019 1:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / August 8, 2019 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies*, today announced the appointment of Nicolas Leupin, M.D., MBA, to the role of Chief Medical Officer and Member of Management Board as of September 1, 2019. Dr. Leupin will succeed Chief Medical Officer Andreas Harstrick, M.D., who will remain with the...

Read more
Continuous Augmentation of Governance Structure, The Board of Great Bay Bio Welcomes a New Member
BiotechnologyCompany UpdateManagement Changes

Continuous Augmentation of Governance Structure, The Board of Great Bay Bio Welcomes a New Member

August 1, 2019 9:25 AM

HONG KONG, CHINA / ACCESSWIRE / August 1, 2019 / Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung. This is now a critical time for Great Bay Bio for rapid development of its core competitive competencies. The...

Read more
Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update
BiotechnologyCompany Update

Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update

August 1, 2019 7:00 AM

Company to Host an Investor Conference Call on Thursday, August 1, 2019 at 8:00 AM EDT BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today reported its cash position for the second quarter of 2019 ended June 30, 2019, and...

Read more
Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors
BiotechnologyCompany Update

Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors

August 1, 2019 6:55 AM

BOSTON, MA / ACCESSWIRE / August 1, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that Maya R. Said, Sc.D., has joined the Company’s Board of Directors. Dr. Said is the Founder and Chief Executive Officer of Outcomes4Me Inc., a health...

Read more
Angle PLC Announces Preliminary Results for the year ended 30 April 2019
BiotechnologyEarningsRegulatory

Angle PLC Announces Preliminary Results for the year ended 30 April 2019

July 31, 2019 2:00 AM

BUILDING ON A LEADING POSITION IN THE LIQUID BIOPSY MARKET FDA SUBMISSION ON TRACK FOLLOWING POSITIVE RESULTS FROM BREAST CANCER CLINICAL STUDY GUILDFORD, SURREY / ACCESSWIRE / July 31, 2019 / ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, today announces unaudited results for the year ended 30 April 2019. Operational Highlights 400 subject FDA clinical study enrolment using the Parsortix® system in...

Read more
Dyadic to Report Second Quarter 2019  Financial Results on Tuesday August 13, 2019
BiotechnologyConference CallEarnings

Dyadic to Report Second Quarter 2019 Financial Results on Tuesday August 13, 2019

July 30, 2019 4:00 PM

JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?